HISTOLOGICAL SPECTRUM OF PREMALIGNANT AND PREINVASIVE MALIGNANT LESIONS IN CYTOLOGICALLY AND RADIOLOGICALLY DIAGNOSED BENIGN BREAST LESIONS-OUR EXPERIENCE IN A TERTIARY CARE HOSPITAL

JABIN MUSFIQUE; LEENA TALUKDAR; MANOJ BARMAN

doi:10.22159/ijcpr.2023v15i6.3086

Authors

JABIN MUSFIQUE Department of Pathology, Gauhati Medical College and Hospital, Narakasur Hilltop, Bhangagarh, Guwahati-781032, Assam, India
LEENA TALUKDAR Department of Pathology, Gauhati Medical College and Hospital, Narakasur Hilltop, Bhangagarh, Guwahati-781032, Assam, India
MANOJ BARMAN Department of Pathology, Gauhati Medical College and Hospital, Narakasur Hilltop, Bhangagarh, Guwahati-781032, Assam, India

DOI:

https://doi.org/10.22159/ijcpr.2023v15i6.3086

Keywords:

Breast, Pre-malignant, Atypical hyperplasia, FNAC

Abstract

Objective: The aim of this study is to detect precancerous lesions and intraductal (in situ) malignancies in cytologically and radiologically diagnosed benign breast lesions and its prevalence in different age groups.

Methods: A total of 448 cases of breast lumps were diagnosed cytological as benign breast lesions in our cytology division from july 2022 to june 2023. Of these, 148 cases were available for histopathological examination.

Results: On Histopathology, 122 cases (82.4%) were diagnosed as benign lesions. 19 (12.8%) cases were found to harbour pre-malignant lesions, 06 (4.0%) cases as in-situ carcinomas and 1 (0.6%) case of encapsulated papillary carcinoma without invasion.

Conclusion: To conclude, prevention of development of carcinoma of breast is the key step to reduce the burden of morbidity and mortality. Recognising pre-malignant lesions can go a long way in reducing development of invasive carcinoma, for which histopathological examination is the most helpful tool. Thus any benign breast lesions that have been detected to harbour pre-malignant changes must be placed into a separate group than from purely benign breast lesions. These groups must be followed up and treated according to standard available protocols.

Downloads

Download data is not yet available.

References

Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153-6. doi: 10.1002/ijc.1440, PMID 11668491.

Sewell CW. Pathology of high-risk breast lesions and ductal carcinoma in situ. Radiol Clin North Am. 2004;42(5):821-30. doi: 10.1016/j.rcl.2004.03.013, PMID 15337418.

Jacobs TW, Connolly JL, Schnitt SJ. Nonmalignant lesions in breast core needle biopsies: to excise or not to excise? Am J Surg Pathol. 2002;26(9):1095-110. doi: 10.1097/00000478-200209000-00001, PMID 12218567.

Ernster VL, Ballard Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94(20):1546-54. doi: 10.1093/jnci/94.20.1546, PMID 12381707.

Simpson JF. Update on atypical epithelial hyperplasia and ductal carcinoma in situ. Pathology. 2009;41(1):36-9. doi: 10.1080/00313020802568097, PMID 19089738.

Gutwein LG, Ang DN, Liu H, Marshall JK, Hochwald SN, Copeland EM. Utilization of minimally invasive breast biopsy for the evaluation of suspicious breast lesions. Am J Surg. 2011;202(2):127-32. doi: 10.1016/j.amjsurg.2010.09.005, PMID 21295284.

Chandanwale S, Kaur S, Nair R, Sheth J, Nikam S, Ansari J. Precancerous breast lesions in benign breast lesions: a review of 430 benign breast lesions. Clin Cancer Investig J. 2017;6(1):30-4. doi: 10.4103/ccij.ccij_7_17.

Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353(3):229-37. doi: 10.1056/NEJMoa044383, PMID 16034008.

Hartmann LC, Radisky DC, Frost MH, Santen RJ, Vierkant RA, Benetti LL. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila). 2014;7(2):211-7. doi: 10.1158/1940-6207.CAPR-13-0222, PMID 24480577.

London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992;267(7):941-4. doi: 10.1001/jama.1992.03480070057030, PMID 1734106.

Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985;55(11):2698-708. doi: 10.1002/1097-0142(19850601)55:11<2698::aid-cncr2820551127>3.0.co;2-a, PMID 2986821.

Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA. Stratification of breast cancer risk in women with atypia: a mayo cohort study. J Clin Oncol. 2007;25(19):2671-7. doi: 10.1200/JCO.2006.09.0217, PMID 17563394.

Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003;361(9352):125-9. doi: 10.1016/S0140-6736(03)12230-1, PMID 12531579.

Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99(4):283-90. doi: 10.1093/jnci/djk050, PMID 17312305.

Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255-69. doi: 10.1200/JCO.2013.54.2258.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076, PMID 20404000.

Goss PE, Ingle JN, Ales Martinez JE, Cheung AM, Chlebowski RT, Wactawski Wende J. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381-91. doi: 10.1056/NEJMoa1103507, PMID 21639806.

Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 2012;36(3):237-48. doi: 10.1016/j.canep.2012.02.007, PMID 22459198.

Van de Vijver MJ, Peterse H. The diagnosis and management of pre-invasive breast disease: pathological diagnosis–problems with existing classifications. Breast Cancer Res. 2003;5(5):269. doi: 10.1186/bcr629, PMID 12927038.

Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian tamoxifen prevention study. Lancet. 1998;352(9122):93-7. doi: 10.1016/s0140-6736(98)85011-3, PMID 9672273.

Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P, Italian Tamoxifen Study Group. Tamoxifen for breast cancer among hysterectomised women. Lancet. 2002;359(9312):1122-4. doi: 10.1016/S0140-6736(02)08159-X, PMID 11943263.

Fitzgibbons PL, Henson DE, Hutter RV. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med. 1998;122(12):1053-5, PMID 9870852.

Schreer I, Lüttges J. Precursor lesions of invasive breast cancer. Eur J Radiol. 2005;54(1):62-71. doi: 10.1016/j.ejrad.2004.11.014, PMID 15797294.

Santen RJ, Mansel R. Benign breast disorders. N Engl J Med. 2005;353(3):275-85. doi: 10.1056/NEJMra035692, PMID 16034013.

Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol. 2011;223(2):307-17. doi: 10.1002/path.2808, PMID 21125683.

Tavassoli FA, Norris HJ. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer. 1990;65(3):518-29. doi: 10.1002/1097-0142(19900201)65:3<518::aid-cncr2820650324>3.0.co;2-o, PMID 2297643.

Worsham MJ, Abrams J, Raju U, Kapke A, Lu M, Cheng J. Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population. Breast J. 2007;13(2):115-21. doi: 10.1111/j.1524-4741.2007.00388.x, PMID 17319851.

Bodian CA, Perzin KH, Lattes R, Hoffmann P, Abernathy TG. Prognostic significance of benign proliferative breast disease. Cancer. 1993;71(12):3896-907. doi: 10.1002/1097-0142(19930615)71:12<3896::aid-cncr2820711217>3.0.co;2-i, PMID 8389654.

Moskowitz M, Gartside P, Wirman JA, McLaughlin C. Proliferative disorders of the breast as risk factors for breast cancer in a self-selected screened population: pathologic markers. Radiology. 1980;134(2):289-91. doi: 10.1148/radiology.134.2.7352201, PMID 7352201.

Venegas R, Rutgers JL, Cameron BL, Vargas H, Butler JA. Fine needle aspiration cytology of breast ductal carcinoma in situ. Acta Cytol. 1994 Mar-Apr;38(2):136-43. PMID 8147202.